11 Hot Growth Stocks to Invest in Now
On October 16, Tim Urbanowicz, Innovator Capital Management chief investment strategist, joined CNBC Television for an interview.
Stoke Therapeutics Inc. (STOK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lynx1 Capital Management Weston Nichols | 5,404,674 | $109,881,253 | 22.37% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 4,633,838 | $108,895,193 | 0.79% | |
| 3. | Redmile Group Jeremy Green | 4,175,542 | $98,125,237 | -5% | 9.55% |
| 4. | Siren L.L.C. Raymond Debbane | 2,247,347 | $52,812,655 | 2.07% | |
| 5. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,657,096 | $38,941,756 | 1.58% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.00 | 375,000 | $14,625,000.00 | 17,161,713 | 2020-11-24 | Filing | |
| $39.00 | 375,000 | $14,625,000.00 | 17,161,713 | 2020-11-24 | Filing | |
| $29.24 | 104,873 | $3,066,843.09 | 3,560,682 | 2019-11-04 | Filing | |
| $28.61 | 8,598 | $245,950.09 | 3,455,809 | 2019-11-01 | Filing | |
| $28.15 | 18,747 | $527,658.69 | 3,447,211 | 2019-10-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $32.61 | 2,678 | $87,337.08 | 11,831 | 2025-12-08 | Filing | |
| $31.60 | 1,300 | $41,074.28 | 14,509 | 2025-12-08 | Filing | |
| $33.10 | 1,331 | $44,061.56 | 49,124 | 2025-12-08 | Filing | |
| $32.52 | 8,274 | $269,070.48 | 50,455 | 2025-12-08 | Filing | |
| $31.44 | 3,825 | $120,253.03 | 58,729 | 2025-12-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,865,057 | $161,328,840 | 0.01% | |
| 2. | 5,987,441 | $140,704,869 | 0% | |
| 3. | 5,123,525 | $120,402,838 | 1.48% | |
| 4. | 3,537,050 | $83,120,676 | 0.01% | |
| 5. | 3,173,258 | $74,571,563 | 0.12% |
News See All
10 Small Cap Stocks with High Potential
As we transition from a tumultuous summer in the financial markets, characterized by rising expectations for interest rate cuts and the consequent impacts on stock and bond performances, investors are...
Is STOK A Good Stock To Buy Now?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Here is What Hedge Funds Think About Stoke Therapeutics, Inc. (STOK)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC.
Hedge Funds Are Selling Stoke Therapeutics, Inc. (STOK)
We can judge whether Stoke Therapeutics, Inc. (NASDAQ:STOK) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas.
Hedge Funds Have Never Been This Bullish On Stoke Therapeutics, Inc. (STOK)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
Hedge Fund Resource Center Billionaire Hedge Funds
